Avadel Pharmaceuticals plc (AVDL) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
188
First IPO Date
June 07, 1996
| Name | Title | Pay | Year Born |
| Gregory J. Divis Jr. | Chief Executive Officer & Director | 677,400 | 1967 |
| Thomas S. McHugh | Senior Vice President, Principal Financial and Accounting Officer & Chief Financial Officer | 530,119 | 1965 |
| Jerad G. Seurer | General Counsel, Company Secretary & Compliance Officer | 634,700 | 1974 |
| Jennifer Gudeman | Senior Vice President of Medical & Clinical Affairs | 0 | N/A |
| Marla Scarola | Senior Vice President of Regulatory & Quality | 0 | N/A |
| Jason Vaughn | Senior Vice President of Technical Operations | 0 | N/A |
| Polly A. Murphy | Chief Business Officer | 0 | 1965 |
| Gregory J. Davis | Vice President of Corporate and Business Development | 0 | 1965 |
| Angie Woods | Vice President of People & Culture | 0 | N/A |
| Susan Rodriguez | Chief Operating Officer | 0 | 1965 |
Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.